While CD30+ expression by lymphoid cells is a hallmarker of lymphocyte activation, lymphoproliferative disorders differ in their clinical presentation and histological features as well as their course, prognosis, and treatment (Kempf et al., 2018). This evidence concerns the gene TNFRSF8 and lymphoproliferative syndrome.